Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Manufacturing
  • Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
  • Manufacturing

Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb

PharmaTimes

Aragen scales Daretabart to commercial-ready production following rapid 9month tech transfer

Read full story

pharminent June 2, 2026 (Last updated: June 4, 2026)

PharmaTimes

Aragen scales Daretabart to commercial-ready production following rapid 9month tech transfer

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs
Next: BMS secures FDA acceptance for Camzyos sNDA

Related Stories

  • Manufacturing

SK pharmteco Launches SKyvec Viral Vector Platform for Gene Therapy

pharminent June 24, 2026
  • Manufacturing

pharminent June 17, 2026
  • Manufacturing

Eisai claims UK grant to expand manufacturing site

pharminent June 15, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.